{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T22:21:04Z","timestamp":1761862864148},"reference-count":32,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2009,7,23]],"date-time":"2009-07-23T00:00:00Z","timestamp":1248307200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cathet Cardio Intervent"],"published-print":{"date-parts":[[2009,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:styled-content>Background:<\/jats:styled-content> The use of drug eluting stents (DES) in patients with a successfully recanalized chronic total occlusion (CTO) has been associated with a significant decrease in the need for repeat revascularization, and a favorable short\u2010term clinical outcome when compared with the use of bare metal stents (BMS). Our group, however, has previously reported similar rates of target lesion revascularisation (TLR) and major adverse cardiovascular events (MACE) at 3 years follow\u2010up in patients with a successfully opened CTO who were treated with either a sirolimus eluting stent (SES) or a BMS. The objective of this report was to evaluate the outcomes of these patients at 5\u2010years clinical follow\u2010up. <jats:styled-content>Methods and Results:<\/jats:styled-content> A total of 140 (BMS 64, SES 76) patients with successfully opened CTOs were included. Seven patients died in the BMS group whilst nine patients died in the SES group (<jats:italic>P<\/jats:italic> = 0.90). Noncardiac death was the major component of all\u2010cause mortality (11 noncardiac deaths vs. 5 cardiac). There were two and three myocardial infarctions (MI) in the BMS and SES group, respectively (<jats:italic>P<\/jats:italic> = 1.0). The composite of death and MI occurred in seven (10.9%) and eleven (14.5%) patients in the BMS and SES group, respectively (<jats:italic>P<\/jats:italic> = 0.53). Clinically driven TLR was performed in eight patients (12.5%) in the BMS group, and five (6.6%) in the SES group (<jats:italic>P<\/jats:italic> = 0.26). Non\u2010TLR target vessel revascularization was performed in one patient in the BMS group, and four in the SES group (<jats:italic>P<\/jats:italic> = 0.37). The 5\u2010year device\u2010oriented cumulative MACE rate was 15.6% and 11.8% in the BMS and SES group, respectively (<jats:italic>P<\/jats:italic> = 0.56). <jats:styled-content>Conclusion:<\/jats:styled-content> In patients with a successfully treated CTO, clinical outcome after 5 years was similar between SES and BMS, however, clinically driven TLR was slightly higher in the BMS group. \u00a9 2009 Wiley\u2010Liss, Inc.<\/jats:p>","DOI":"10.1002\/ccd.22230","type":"journal-article","created":{"date-parts":[[2009,7,23]],"date-time":"2009-07-23T17:14:55Z","timestamp":1248369295000},"page":"979-986","source":"Crossref","is-referenced-by-count":23,"title":["Five\u2010year clinical outcomes after coronary stenting of chronic total occlusion using sirolimus\u2010eluting stents: Insights from the rapamycin\u2010eluting stent evaluated at Rotterdam Cardiology Hospital\u2014(Research) Registry"],"prefix":"10.1002","volume":"74","author":[{"given":"Zhu Jun","family":"Shen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hector M.","family":"Garc\u00eda\u2010Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scot","family":"Garg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshinobu","family":"Onuma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisanne","family":"Schenkeveld","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ron T.","family":"van Domburg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick W.","family":"Serruys","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,9,14]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehi191"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2006.05.018"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2004.09.040"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2004.08.088"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(98)00440-8"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2004.01.045"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/ccd.21249"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000109138.84579.FA"},{"key":"e_1_2_7_10_2","first-page":"78","volume-title":"Modern Epidemiology","author":"Rothman K","year":"1998"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.106.685313"},{"key":"e_1_2_7_12_2","first-page":"452","article-title":"A new percutaneous porcine coronary model of chronic total occlusion","volume":"17","author":"Song W","year":"2005","journal-title":"J Invasive Cardiol"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.105.583716"},{"key":"e_1_2_7_14_2","first-page":"1518","article-title":"Impact of drug\u2010eluting stents on transferring treatment with coronary surgical revascularization among patients initially admitted to department of internal medicine","volume":"87","author":"He LQ","year":"2007","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(01)01349-3"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2006.12.040"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehi498"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2008.06.059"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.106.613588"},{"key":"e_1_2_7_20_2","first-page":"193","article-title":"Drug\u2010eluting stent implantation for chronic total occlusions: Comparison between the Sirolimus\u2010 and Paclitaxel\u2010eluting stent","volume":"1","author":"Hoye A","year":"2005","journal-title":"EuroIntervention"},{"key":"e_1_2_7_21_2","first-page":"651","article-title":"Clinical outcome of patients with diabetes mellitus and chronic total occlusion treated with drug\u2010eluting stents","volume":"20","author":"De Felice F","year":"2008","journal-title":"J Invasive Cardiol"},{"key":"e_1_2_7_22_2","first-page":"643","article-title":"Long\u2010term outcomes of drug\u2010eluting versus bare\u2010metal stent implantation in patients with chronic total coronary artery occlusions","volume":"122","author":"Han YL","year":"2009","journal-title":"Chin Med J (Engl)"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2008.08.025"},{"key":"e_1_2_7_24_2","unstructured":"SerruysPW.SPIRIT 2 study: A clinical evaluation of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions. Late\u2010breaking clinical trials 3. American College of Cardiology Scientific Sessions\/i2 Summit\u2010SCAI Annual Meeting Chicago. March 31 2008."},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.108.803528"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2006.08.033"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2007.06.029"},{"key":"e_1_2_7_28_2","doi-asserted-by":"publisher","DOI":"10.4244\/EIJV4I5A97"},{"key":"e_1_2_7_29_2","doi-asserted-by":"publisher","DOI":"10.1586\/14779072.5.2.231"},{"key":"e_1_2_7_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2005.06.076"},{"key":"e_1_2_7_31_2","doi-asserted-by":"crossref","first-page":"464","DOI":"10.4244\/EIJV4I4A80","article-title":"The relative safety and efficacy of bare\u2010metal and drug\u2010eluting stents in low and high\u2010risk patient subsets. An epidemiological analysis of three sequential cohorts of consecutive all comers (n = 6129)","volume":"4","author":"Daemen. J","year":"2008","journal-title":"EuroIntervention"},{"key":"e_1_2_7_32_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehn357"},{"key":"e_1_2_7_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2006.02.060"}],"container-title":["Catheterization and Cardiovascular Interventions"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fccd.22230","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ccd.22230","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,13]],"date-time":"2023-11-13T22:20:58Z","timestamp":1699914058000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ccd.22230"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9,14]]},"references-count":32,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2009,12]]}},"alternative-id":["10.1002\/ccd.22230"],"URL":"https:\/\/doi.org\/10.1002\/ccd.22230","archive":["Portico"],"relation":{},"ISSN":["1522-1946","1522-726X"],"issn-type":[{"value":"1522-1946","type":"print"},{"value":"1522-726X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,9,14]]}}}